

Compounds of Formula (1.0.0) are described, wherein A is for example aryl, heteroaryl or heterocyclyl, Y is preferably -C(=O)-; B is independently selected from a group of moieties, the most preferred of which are those of partial Formulas (1.1.2) and (1.1.6), and E is a single bond; oxygen; 1,1-cyclopropyl; C(CH₃)₂; CF₂; or a bridging moiety of partial Formula (1.9.0), where R¹_a is hydrogen when R¹ has the meaning of a monovalent substituent; and R¹_a is a single bond when R¹ has the meaning of a divalent substituent. Said compounds are useful in methods of treating or preventing an inflammatory, autoimmune or respiratory disease by inhibiting cell adhesion and consequent or associated pathogenic processes subsequently mediated by VLA-4.